Literature DB >> 13678470

Lipid rafts and HIV pathogenesis: virion-associated cholesterol is required for fusion and infection of susceptible cells.

Zhaohao Liao1, David R Graham, James E K Hildreth.   

Abstract

We have shown that HIV budding occurs at cholesterol-rich membrane microdomains called lipid rafts (Nguyen and Hildreth, J Virol 2000;74:3264-3272). This observation prompted us to examine the role in HIV entry of cholesterol in the membrane of cells. We recently reported that host cell cholesterol is required for HIV infection (Liao et al., AIDS Res Hum Retroviruses 2001;17:1009-1019). In the present study we examined the role of virion-associated cholesterol in HIV infection by modulating the cholesterol content of virions and infected cells with 2-hydoxypropyl-beta-cyclodextrin (beta-cyclodextrin). Our results show that removal of cholesterol from the membrane of HIV-infected cells dramatically lowered virus release and that virions released from cholesterol-depleted cells are minimally infectious. Exposure of infectious HIV particles to beta-cyclodextrin resulted in a dose-dependent inactivation of the virus. In both cases, the effect was attributable to loss of cholesterol and could be reversed by replenishing cholesterol. beta-Cyclodextrin-treated, noninfectious HIV retained its ability to bind cells. Western blot, p24 core ELISA, and reverse transcription assays indicated that virions remained intact after treatment with beta-cyclodextrin at concentrations that abolished infectivity. Electron microscopy revealed that beta-cyclodextrin-treated HIV had a morphology very similar to that of untreated virus. R18 fluorescence dequenching studies showed that beta-cyclodextrin-treated HIV did not fuse to the membrane of susceptible cells. Dequenching was restored by replenishing virion-associated cholesterol. The results indicate that cholesterol in HIV particles is strictly required for fusion and infectivity. These observations in combination with those of past studies indicate beta-cyclodextrin to be an excellent candidate for use as a chemical barrier for AIDS prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13678470     DOI: 10.1089/088922203322280900

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  90 in total

1.  Overactivation of plasmacytoid dendritic cells inhibits antiviral T-cell responses: a model for HIV immunopathogenesis.

Authors:  Adriano Boasso; Caroline M Royle; Spyridon Doumazos; Veronica N Aquino; Mara Biasin; Luca Piacentini; Barbara Tavano; Dietmar Fuchs; Francesco Mazzotta; Sergio Lo Caputo; Gene M Shearer; Mario Clerici; David R Graham
Journal:  Blood       Date:  2011-09-19       Impact factor: 22.113

Review 2.  Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.

Authors:  Lifeng Cai; Miriam Gochin; Keliang Liu
Journal:  Curr Top Med Chem       Date:  2011-12       Impact factor: 3.295

3.  HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes.

Authors:  Tommy Tong; Ema T Crooks; Keiko Osawa; James M Binley
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

Review 4.  Role of sphingolipids in microbial pathogenesis.

Authors:  Lena J Heung; Chiara Luberto; Maurizio Del Poeta
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

Review 5.  Early events of HIV-1 infection: can signaling be the next therapeutic target?

Authors:  Kate L Jones; Redmond P Smyth; Cândida F Pereira; Paul U Cameron; Sharon R Lewin; Anthony Jaworowski; Johnson Mak
Journal:  J Neuroimmune Pharmacol       Date:  2011-03-05       Impact factor: 4.147

6.  Phase fluctuations on the micron-submicron scale in GUVs composed of a binary lipid mixture.

Authors:  Anna Celli; Sabrina Beretta; Enrico Gratton
Journal:  Biophys J       Date:  2007-08-31       Impact factor: 4.033

7.  Inhibition of anthrax protective antigen outside and inside the cell.

Authors:  Marina V Backer; Vimal Patel; Brian T Jehning; Kevin P Claffey; Vladimir A Karginov; Joseph M Backer
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

8.  PPARgamma and LXR signaling inhibit dendritic cell-mediated HIV-1 capture and trans-infection.

Authors:  Timothy M Hanley; Wendy Blay Puryear; Suryaram Gummuluru; Gregory A Viglianti
Journal:  PLoS Pathog       Date:  2010-07-01       Impact factor: 6.823

9.  Live cell visualization of the interactions between HIV-1 Gag and the cellular RNA-binding protein Staufen1.

Authors:  Miroslav P Milev; Chris M Brown; Andrew J Mouland
Journal:  Retrovirology       Date:  2010-05-10       Impact factor: 4.602

Review 10.  Apolipoprotein E genotype and hepatitis C, HIV and herpes simplex disease risk: a literature review.

Authors:  Inga Kuhlmann; Anne Marie Minihane; Patricia Huebbe; Almut Nebel; Gerald Rimbach
Journal:  Lipids Health Dis       Date:  2010-01-28       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.